Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Alliance with Molecular Profiling Institute to introduce breast cancer test
January 20th, 2005
Agendia BV (Amsterdam, The Netherlands) and the Molecular Profiling Institute (MPI, Phoenix, Arizona) announced that they have reached agreement for distribution of MammaPrint in the U.S. MammaPrint has successfully reached level 3 in evidence-based medicine in an independent international validation under the lead of Transbig, an international translational research network. "We are very pleased to have MPI as a partner for the USA, which is a key market for Agendia's MammaPrint." "It is important to point out that the potential prospects of the cooperation between Agendia and MPI go much further than expanding the MammaPrint market to the...
Source: Women's Health Weekly (2005-01-20)
|
